# Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)

Source: https://onco.cc/trials/nct03722420/  
OnCo record `nct03722420` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Imatinib in chronic myeloid leukaemia, run by Il-Yang Pharm. Co., Ltd., active and no longer recruiting.

## Summary

Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) is a phase 3 interventional study registered as NCT03722420 by Il-Yang Pharm. Co., Ltd., with 238 participants enrolled, started 2018-12-28 and due to reach its primary completion in 2023-03-03. Interventions recorded: Radotinib and Imatinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03722420
- Phase: 3
- Setting: A Phase III, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Chinese Patients in Chronic Phase
- Sponsor: Il-Yang Pharm. Co., Ltd.
- Enrolled: 238

## Sources

- ClinicalTrials.gov NCT03722420: https://clinicaltrials.gov/study/NCT03722420

## Connected records

- cancers: [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- drugs: [Imatinib](https://onco.cc/drugs/imatinib/), [Radotinib](https://onco.cc/drugs/radotinib/)

---
JSON: https://onco.cc/api/v1/entities/nct03722420.json